HannahKChoeMD

Hematologic Oncology

Physician

Dr. Choe is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
460 W 10th Ave
Fl 5
Columbus, OH 43210
Phone+1 614-293-3196

Fax+1 614-293-7526

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2014 - 2017
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2011 - 2014
Indiana University School of MedicineClass of 2011

A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) Start of enrollment: 2022 Jun 16
Terminated
Phase 3
Roles: Contact
Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD Start of enrollment: 2022 Apr 19
Terminated
Phase 1, Phase 2
Roles: Sponsor-Investigator, Principal Investigator, Contact
High Dose Vitamin A in Preventing Gastrointestinal GVHD in Participants Undergoing Donor Stem Cell Transplant Start of enrollment: 2020 Feb 07
Recruiting
Not Applicable
Roles: Principal Investigator, Contact
Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease Start of enrollment: 2012 Feb 20
Recruiting
Roles: Principal Investigator, Contact
Join now to see all

PubMed

Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group.
Nikolaos Katsivelos, Nikolaos Spyrou, Daniela Weber, Ingrid Vasova, Francis Ayuk
Transplantation and Cellular Therapy. 2024-11-26
A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease.
Vijaya Raj Bhatt, Valerie K Shostrom, Hannah K Choe, Betty K Hamilton, Krishna Gundabolu
Journal of Clinical Oncology. 2024-11-20
Impact of chronic graft--host disease on non-relapse mortality and survival.
Justin Jiang, Audrey M Sigmund, Qiuhong Zhao, Patrick Elder, Sumithira Vasu
Leukemia & Lymphoma. 2024-11-01

Abstracts/Posters

The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease
Hannah K. Choe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation
Hannah K. Choe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Bromodomain and Extraterminal (BET) Domain Inhibition with PLX51107 and PLX2853 Improves Survival and Decreases Acute GVHD Severity in Murine Models
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
PRMT5 Is Upregulated in Activated T Cells and Is a Novel Therapeutic Target for Acute Gvhd
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (Axatilimab-Csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual MeetingNovember 5th, 2024
$Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting$
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual MeetingApril 19th, 2024